Richard Gray
Statistician behind the Early Breast Cancer Trialists' meta-analyses that set the global evidence base for adjuvant therapy.
Overview
Richard Gray leads the secretariat of the Early Breast Cancer Trialists' Collaborative Group, whose individual-patient-data meta-analyses of hundreds of trials quantified the benefits of tamoxifen, aromatase inhibitors, chemotherapy, radiotherapy and bisphosphonates and underpin every breast cancer guideline. He also led the QUASAR colorectal adjuvant trials and the aTTom trial of ten years of tamoxifen.
Pages like this
not linked directly; found by shared links- PersonSir Richard Peto
Shares Oxford Cancer – Oxford University Hospitals and University of Oxford, HR-positive / HER2-negative breast cancer and the tag meta-analysis.
- PersonJudith M. Bliss
Shares HR-positive / HER2-negative breast cancer and the tags biostatistics, breast.
- PersonPrudence A. Francis
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
- PersonMitch Dowsett
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
- PersonJack Cuzick
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag breast.
- ProductMegestrol acetate
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- PersonAnn H. Partridge
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- IdeaRotate between drugs on a fixed schedule instead of waiting for failure
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.